This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EPAM, Synacor Are Class of IPO Calendar

NEW YORK ( TheStreet -- Despite all the hype from the Facebook filing, 2012 is off to a slow start when it comes to IPO activity.

According to Renaissance Capital, only 8 IPOs have priced so far in the U.S. and just $800 million in proceeds have been raised. This week, 12 offerings are still on the docket after Erickson Air-Crane postponed.

Unfortunately, this looks like a case of quantity over quality and there's a lot to avoid. Caesars Entertainment (CZR - Get Report) didn't exactly get off to a promising start when it delayed its pricing on Monday, citing a "technical glitch."

The casino operator was able to pull off the pricing on Tuesday though, raising $16 million through the sale of 1.8 million shares at $9 each, the midpoint of its range. This one looks like a real gamble as the company is highly leveraged and will probably use new shareholder money to relieve some of debt pressure.

Caesars isn't the only dodgy offering this week, Ceres (CERE - Get Report) is a close second. It's a biotech agriculture company that uses crops to generate fuel. The only problem is that the government is beginning to extract itself out of the energy crop subsidy business.

Plus Ceres competes against giants like Dow Chemical (DOW) and Monsanto (MON). Ceres is hoping to raise $110 million on Thursday, seeking to sell 5 million shares at $21 to $23 each. Then there's GSE Holdings (GSE), which tried to go public last year and postponed as the IPO market ground to a halt. GSE makes plastic membrane covers for use at garbage dumps and mines. It's a loss maker that's looking to sell 7 million shares at between $8 to $10 each, aiming to raise $63 million by Friday.

Cancer drug developers are a hot IPO trend so far this year and the current week brings two more to the market. ChemoCentryx (CCXI) is a biopharma company focused on discovering, developing and then commercializing drugs to treat autoimmune diseases and cancer.

Its hook is small molecule targeting, and the company wants to raise $60 million for further clinical testing. It's offering 4 million shares with a pricing range of $14 to $16 per share. A price-to-sales ratio of 68.3X (at the midpoint of the range) for a company with no products seems expensive.

TVAX Biomedical (TVAX) is looking for $20 million from the market in order to fund its clinical trials too but it's really too small for retail investors to bother with.

Roundy's Parent (RNDY - Get Report)is the largest offering of the week, and it priced on Tuesday, reportedly selling 19.2 million shares at $8.50 each, raising $163 million.

A grocery store chain based in the Midwest, Roundy's sold more stock than expected but at a lower price compared to a projected range of $10-$12 each. It had been looking to bring in $200 million. Roundy's has good cash flow and says it plans to pay a hefty 8.4% dividend.

IPO Desktop President Francis Gaskins warns investors not to get sucked into those promises. "In order to pay that dividend, Roundy's would have to pay out 73% of its net income, leaving little room for growth capital," said Gaskins. He also points out that its competitors Safeway (SWY) and Kroger (KR) only pay out 36% of their earnings.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CERE $1.09 6.90%
CZR $7.56 3.60%
EPAM $78.42 3.70%
RNDY $2.57 4.50%
SYNC $1.35 -2.20%


Chart of I:DJI
DOW 16,775.23 +302.86 1.84%
S&P 500 1,986.05 +34.69 1.78%
NASDAQ 4,776.9060 +69.1310 1.47%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs